Home

Download

Statistics

Examples

Help

Contact

	Fusion Gene Summary
	Fusion Gene ORF analysis
	Fusion Genomic Features
	Fusion Protein Features
	Fusion Gene Sequence
	Fusion Gene PPI analysis
	Related Drugs
	Related Diseases

Fusion gene:MAP2K4-CD79B (FusionGDB2 ID:51206)

Fusion Gene Summary for MAP2K4-CD79B

Fusion gene summary

Fusion gene information	Fusion gene name: MAP2K4-CD79B
	Fusion gene ID: 51206
		Hgene	Tgene
	Gene symbol	MAP2K4	CD79B
	Gene ID	6416	974
	Gene name	mitogen-activated protein kinase kinase 4	CD79b molecule
	Synonyms	JNKK\|JNKK1\|MAPKK4\|MEK4\|MKK4\|PRKMK4\|SAPKK-1\|SAPKK1\|SEK1\|SERK1\|SKK1	AGM6\|B29\|IGB
	Cytomap	17p12	17q23.3
	Type of gene	protein-coding	protein-coding
	Description	dual specificity mitogen-activated protein kinase kinase 4JNK-activated kinase 1JNK-activating kinase 1MAP kinase kinase 4MAPK/ERK kinase 4MAPKK 4MEK 4SAPK/ERK kinase 1c-Jun N-terminal kinase kinase 1stress-activated protein kinase kinase 1	B-cell antigen receptor complex-associated protein beta chainB-cell-specific glycoprotein B29CD79b antigen (immunoglobulin-associated beta)CD79b molecule, immunoglobulin-associated betaIg-betaimmunoglobulin-associated B29 protein
	Modification date	20200329	20200313
	UniProtAcc	P45985	P40259
	Ensembl transtripts involved in fusion gene	ENST00000353533, ENST00000415385, ENST00000581941,	ENST00000006750, ENST00000349817, ENST00000392795,
Fusion gene scores	* DoF score	10 X 4 X 7=280	2 X 3 X 2=12
	# samples	13	3
	** MAII score	log2(13/280*10)=-1.10691520391651 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0	log2(3/12*10)=1.32192809488736 effective Gene in Pan-Cancer Fusion Genes (eGinPCFGs). DoF>8 and MAII>0
Context	PubMed: MAP2K4 [Title/Abstract] AND CD79B [Title/Abstract] AND fusion [Title/Abstract]
Most frequent breakpoint	MAP2K4(11958308)-CD79B(62008745), # samples:3
Anticipated loss of major functional domain due to fusion event.	MAP2K4-CD79B seems lost the major protein functional domain in Hgene partner, which is a CGC due to the frame-shifted ORF. MAP2K4-CD79B seems lost the major protein functional domain in Hgene partner, which is a IUPHAR drug target due to the frame-shifted ORF. MAP2K4-CD79B seems lost the major protein functional domain in Hgene partner, which is a kinase due to the frame-shifted ORF. MAP2K4-CD79B seems lost the major protein functional domain in Hgene partner, which is a tumor suppressor due to the frame-shifted ORF. MAP2K4-CD79B seems lost the major protein functional domain in Tgene partner, which is a CGC due to the frame-shifted ORF. MAP2K4-CD79B seems lost the major protein functional domain in Tgene partner, which is a essential gene due to the frame-shifted ORF. MAP2K4-CD79B seems lost the major protein functional domain in Tgene partner, which is a IUPHAR drug target due to the frame-shifted ORF.

* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez

Partner

Gene

GO ID

GO term

PubMed ID

Fusion gene breakpoints across MAP2K4 (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.

Fusion gene breakpoints across CD79B (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.

Fusion gene information from two resources (ChiTars 5.0 and ChimerDB 4.0)
* All genome coordinats were lifted-over on hg19.
* Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser.

Source	Disease	Sample	Hgene	Hchr	Hbp	Hstrand	Tgene	Tchr	Tbp	Tstrand
ChimerDB4	BRCA	TCGA-GI-A2C8-01A	MAP2K4	chr17	11924318	+	CD79B	chr17	62008748	-
ChimerDB4	BRCA	TCGA-GI-A2C8-01A	MAP2K4	chr17	11958308	-	CD79B	chr17	62008745	-
ChimerDB4	BRCA	TCGA-GI-A2C8-01A	MAP2K4	chr17	11958308	+	CD79B	chr17	62008745	-
ChimerDB4	BRCA	TCGA-GI-A2C8	MAP2K4	chr17	11924318	+	CD79B	chr17	62008748	-

Top

Fusion Gene ORF analysis for MAP2K4-CD79B

Open reading frame (ORF) analsis of fusion genes based on Ensembl gene isoform structure.
* Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser.

ORF	Henst	Tenst	Hgene	Hchr	Hbp	Hstrand	Tgene	Tchr	Tbp	Tstrand
Frame-shift	ENST00000353533	ENST00000006750	MAP2K4	chr17	11958308	+	CD79B	chr17	62008745	-
Frame-shift	ENST00000353533	ENST00000349817	MAP2K4	chr17	11958308	+	CD79B	chr17	62008745	-
Frame-shift	ENST00000353533	ENST00000392795	MAP2K4	chr17	11958308	+	CD79B	chr17	62008745	-
Frame-shift	ENST00000415385	ENST00000006750	MAP2K4	chr17	11958308	+	CD79B	chr17	62008745	-
Frame-shift	ENST00000415385	ENST00000349817	MAP2K4	chr17	11958308	+	CD79B	chr17	62008745	-
Frame-shift	ENST00000415385	ENST00000392795	MAP2K4	chr17	11958308	+	CD79B	chr17	62008745	-
In-frame	ENST00000353533	ENST00000006750	MAP2K4	chr17	11924318	+	CD79B	chr17	62008748	-
In-frame	ENST00000353533	ENST00000349817	MAP2K4	chr17	11924318	+	CD79B	chr17	62008748	-
In-frame	ENST00000353533	ENST00000392795	MAP2K4	chr17	11924318	+	CD79B	chr17	62008748	-
In-frame	ENST00000415385	ENST00000006750	MAP2K4	chr17	11924318	+	CD79B	chr17	62008748	-
In-frame	ENST00000415385	ENST00000349817	MAP2K4	chr17	11924318	+	CD79B	chr17	62008748	-
In-frame	ENST00000415385	ENST00000392795	MAP2K4	chr17	11924318	+	CD79B	chr17	62008748	-
intron-3CDS	ENST00000581941	ENST00000006750	MAP2K4	chr17	11958308	+	CD79B	chr17	62008745	-
intron-3CDS	ENST00000581941	ENST00000006750	MAP2K4	chr17	11924318	+	CD79B	chr17	62008748	-
intron-3CDS	ENST00000581941	ENST00000349817	MAP2K4	chr17	11958308	+	CD79B	chr17	62008745	-
intron-3CDS	ENST00000581941	ENST00000349817	MAP2K4	chr17	11924318	+	CD79B	chr17	62008748	-
intron-3CDS	ENST00000581941	ENST00000392795	MAP2K4	chr17	11958308	+	CD79B	chr17	62008745	-
intron-3CDS	ENST00000581941	ENST00000392795	MAP2K4	chr17	11924318	+	CD79B	chr17	62008748	-

ORFfinder result based on the fusion transcript sequence of in-frame fusion genes.

Henst	Tenst	Hgene	Hchr	Hbp	Hstrand	Tgene	Tchr	Tbp	Tstrand	Seq length (transcript)	BP loci (transcript)	Predicted start (transcript)	Predicted stop (transcript)	Seq length (amino acids)
ENST00000353533	MAP2K4	chr17	11924318	+	ENST00000392795	CD79B	chr17	62008748	-	1290	178	1202	51	383
ENST00000353533	MAP2K4	chr17	11924318	+	ENST00000006750	CD79B	chr17	62008748	-	1287	178	1199	51	382
ENST00000353533	MAP2K4	chr17	11924318	+	ENST00000349817	CD79B	chr17	62008748	-	489	178	482	51	143
ENST00000415385	MAP2K4	chr17	11924318	+	ENST00000392795	CD79B	chr17	62008748	-	1280	168	1192	41	383
ENST00000415385	MAP2K4	chr17	11924318	+	ENST00000006750	CD79B	chr17	62008748	-	1277	168	1189	41	382
ENST00000415385	MAP2K4	chr17	11924318	+	ENST00000349817	CD79B	chr17	62008748	-	479	168	472	41	143

DeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.

Henst	Tenst	Hgene	Hchr	Hbp	Hstrand	Tgene	Tchr	Tbp	Tstrand	No-coding score	Coding score
ENST00000353533	ENST00000392795	MAP2K4	chr17	11924318	+	CD79B	chr17	62008748	-	0.004026695	0.9959733
ENST00000353533	ENST00000006750	MAP2K4	chr17	11924318	+	CD79B	chr17	62008748	-	0.004933833	0.99506617
ENST00000353533	ENST00000349817	MAP2K4	chr17	11924318	+	CD79B	chr17	62008748	-	0.000484603	0.9995154
ENST00000415385	ENST00000392795	MAP2K4	chr17	11924318	+	CD79B	chr17	62008748	-	0.004034091	0.99596596
ENST00000415385	ENST00000006750	MAP2K4	chr17	11924318	+	CD79B	chr17	62008748	-	0.00491748	0.9950825
ENST00000415385	ENST00000349817	MAP2K4	chr17	11924318	+	CD79B	chr17	62008748	-	0.000431967	0.99956805

Top

Fusion Genomic Features for MAP2K4-CD79B

FusionAI prediction of the potential fusion gene breakpoint based on the pre-mature RNA sequence context (+/- 5kb of individual partner genes, total 20kb length sequence). FusionAI is a fusion gene breakpoint classifier based on convolutional neural network by comparing the fusion positive and negative sequence context of ~ 20K fusion gene data. From here, we can have the relative potentency of the 20K genomic sequence how individual sequnce will be likely used as the gene fusion breakpoints.

Hgene

Hchr

Hbp

Hstrand

Tgene

Tchr

Tbp

Tstrand

1-p

p (fusion gene breakpoint)

Distribution of 44 human genomic features loci across 20kb length fusion breakpoint regions. We integrated a total of 44 different types of human genomic feature loci information across five big categories including virus integration sites, repeats, structural variants, chromatin states, and gene expression regulation. More details are in help page.

Distribution of 44 human genomic features loci across 20kb length fusion breakpoint regions that are ovelapped with the top 1% feature importance score regions. More details are in help page.

Top

Fusion Protein Features for MAP2K4-CD79B

Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr17:11958308/chr17:62008745)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.

Main function of each fusion partner protein. (from UniProt)

Hgene	Tgene
MAP2K4 P45985	CD79B P40259
FUNCTION: Dual specificity protein kinase which acts as an essential component of the MAP kinase signal transduction pathway. Essential component of the stress-activated protein kinase/c-Jun N-terminal kinase (SAP/JNK) signaling pathway. With MAP2K7/MKK7, is the one of the only known kinase to directly activate the stress-activated protein kinase/c-Jun N-terminal kinases MAPK8/JNK1, MAPK9/JNK2 and MAPK10/JNK3. MAP2K4/MKK4 and MAP2K7/MKK7 both activate the JNKs by phosphorylation, but they differ in their preference for the phosphorylation site in the Thr-Pro-Tyr motif. MAP2K4 shows preference for phosphorylation of the Tyr residue and MAP2K7/MKK7 for the Thr residue. The phosphorylation of the Thr residue by MAP2K7/MKK7 seems to be the prerequisite for JNK activation at least in response to proinflammatory cytokines, while other stimuli activate both MAP2K4/MKK4 and MAP2K7/MKK7 which synergistically phosphorylate JNKs. MAP2K4 is required for maintaining peripheral lymphoid homeostasis. The MKK/JNK signaling pathway is also involved in mitochondrial death signaling pathway, including the release cytochrome c, leading to apoptosis. Whereas MAP2K7/MKK7 exclusively activates JNKs, MAP2K4/MKK4 additionally activates the p38 MAPKs MAPK11, MAPK12, MAPK13 and MAPK14. {ECO:0000269\|PubMed:7716521}.	FUNCTION: Required in cooperation with CD79A for initiation of the signal transduction cascade activated by the B-cell antigen receptor complex (BCR) which leads to internalization of the complex, trafficking to late endosomes and antigen presentation. Enhances phosphorylation of CD79A, possibly by recruiting kinases which phosphorylate CD79A or by recruiting proteins which bind to CD79A and protect it from dephosphorylation. {ECO:0000269\|PubMed:12097390, ECO:0000269\|PubMed:8617796, ECO:0000269\|PubMed:9057631}.

Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at
download page

* Minus value of BPloci means that the break pointn is located before the CDS.

- In-frame and retained protein feature among the 13 regional features.

Partner

Gene

Hbp

Tbp

ENST

Strand

BPexon

TotalExon

Protein feature loci

*BPloci

TotalLen

Protein feature

Protein feature note

Hgene

MAP2K4

chr17:11924318

chr17:62008748

ENST00000353533

5_19

400.0

Compositional bias

Note=Gly/Ser-rich

Hgene

MAP2K4

chr17:11924318

chr17:62008748

ENST00000415385

5_19

411.0

Compositional bias

Note=Gly/Ser-rich

Tgene

CD79B

chr17:11924318

chr17:62008748

ENST00000006750

185_213

230.0

Domain

ITAM

Tgene

CD79B

chr17:11924318

chr17:62008748

ENST00000006750

38_138

230.0

Domain

Note=Ig-like V-type

Tgene

CD79B

chr17:11924318

chr17:62008748

ENST00000349817

185_213

126.0

Domain

ITAM

Tgene

CD79B

chr17:11924318

chr17:62008748

ENST00000349817

38_138

126.0

Domain

Note=Ig-like V-type

Tgene

CD79B

chr17:11924318

chr17:62008748

ENST00000392795

185_213

231.0

Domain

ITAM

Tgene

CD79B

chr17:11924318

chr17:62008748

ENST00000392795

38_138

231.0

Domain

Note=Ig-like V-type

Tgene

CD79B

chr17:11924318

chr17:62008748

ENST00000006750

181_229

230.0

Topological domain

Cytoplasmic

Tgene

CD79B

chr17:11924318

chr17:62008748

ENST00000006750

29_159

230.0

Topological domain

Extracellular

Tgene

CD79B

chr17:11924318

chr17:62008748

ENST00000349817

181_229

126.0

Topological domain

Cytoplasmic

Tgene

CD79B

chr17:11924318

chr17:62008748

ENST00000349817

29_159

126.0

Topological domain

Extracellular

Tgene

CD79B

chr17:11924318

chr17:62008748

ENST00000392795

181_229

231.0

Topological domain

Cytoplasmic

Tgene

CD79B

chr17:11924318

chr17:62008748

ENST00000392795

29_159

231.0

Topological domain

Extracellular

Tgene

CD79B

chr17:11924318

chr17:62008748

ENST00000006750

160_180

230.0

Transmembrane

Helical

Tgene

CD79B

chr17:11924318

chr17:62008748

ENST00000349817

160_180

126.0

Transmembrane

Helical

Tgene

CD79B

chr17:11924318

chr17:62008748

ENST00000392795

160_180

231.0

Transmembrane

Helical

- In-frame and not-retained protein feature among the 13 regional features.

Partner

Gene

Hbp

Tbp

ENST

Strand

BPexon

TotalExon

Protein feature loci

*BPloci

TotalLen

Protein feature

Protein feature note

Hgene

MAP2K4

chr17:11924318

chr17:62008748

ENST00000353533

102_367

400.0

Domain

Protein kinase

Hgene

MAP2K4

chr17:11924318

chr17:62008748

ENST00000415385

102_367

411.0

Domain

Protein kinase

Hgene

MAP2K4

chr17:11924318

chr17:62008748

ENST00000353533

108_116

400.0

Nucleotide binding

ATP

Hgene

MAP2K4

chr17:11924318

chr17:62008748

ENST00000415385

108_116

411.0

Nucleotide binding

ATP

Hgene

MAP2K4

chr17:11924318

chr17:62008748

ENST00000353533

364_387

400.0

Region

Note=DVD domain

Hgene

MAP2K4

chr17:11924318

chr17:62008748

ENST00000353533

37_52

400.0

Region

Note=D domain

Hgene

MAP2K4

chr17:11924318

chr17:62008748

ENST00000415385

364_387

411.0

Region

Note=DVD domain

Hgene

MAP2K4

chr17:11924318

chr17:62008748

ENST00000415385

37_52

411.0

Region

Note=D domain

Top

Fusion Gene Sequence for MAP2K4-CD79B

For in-frame fusion transcripts, we provide the fusion transcript sequences and fusion amino acid sequences. To have fusion amino acid sequence, we ran ORFfinder and chose the longest ORF among the all predicted ones.

>51206_51206_1_MAP2K4-CD79B_MAP2K4_chr17_11924318_ENST00000353533_CD79B_chr17_62008748_ENST00000006750_length(transcript)=1287nt_BP=178nt
GCGAGAGGCCGAGCTTGCTGCATTGCAGCCGCCGCGGCGCCGCTCGGCTCTTCACTCCCAACAATGGCGGCTCCGAGCCCGAGCGGCGGC
GGCGGCTCCGGGGGCGGCAGCGGCAGCGGCACCCCCGGCCCCGTAGGGTCCCCGGCGCCAGGCCACCCGGCCGTCAGCAGCATGCAGGCT
GAGCCAGTACCAGCAGCCAGATCGGAGGACCGGTACCGGAATCCCAAAGGTAGTGCTTGTTCGCGGATCTGGCAGAGCCCACGTTTCATA
GCCAGGAAACGGGGCTTCACGGTGAAAATGCACTGCTACATGAACAGCGCCTCCGGCAATGTGAGCTGGCTCTGGAAGCAGGAGATGGAC
GAGAATCCCCAGCAGCTGAAGCTGGAAAAGGGCCGCATGGAAGAGTCCCAGAACGAATCTCTCGCCACCCTCACCATCCAAGGCATCCGG
TTTGAGGACAATGGCATCTACTTCTGTCAGCAGAAGTGCAACAACACCTCGGAGGTCTACCAGGGCTGCGGCACAGAGCTGCGAGTCATG
GGATTCAGCACCTTGGCACAGCTGAAGCAGAGGAACACGCTGAAGGATGGTATCATCATGATCCAGACGCTGCTGATCATCCTCTTCATC
ATCGTGCCTATCTTCCTGCTGCTGGACAAGGATGACAGCAAGGCTGGCATGGAGGAAGATCACACCTACGAGGGCCTGGACATTGACCAG
ACAGCCACCTATGAGGACATAGTGACGCTGCGGACAGGGGAAGTGAAGTGGTCTGTAGGTGAGCACCCAGGCCAGGAGTGAGAGCCAGGT
CGCCCCATGACCTGGGTGCAGGCTCCCTGGCCTCAGTGACTGCTTCGGAGCTGCCTGGCTCATGGCCCAACCCCTTTCCTGGACCCCCCA
GCTGGCCTCTGAAGCTGGCCCACCAGAGCTGCCATTTGTCTCCAGCCCCTGGTCCCCAGCTCTTGCCAAAGGGCCTGGAGTAGAAGGACA
ACAGGGCAGCAACTTGGAGGGAGTTCTCTGGGGATGGACGGGACCCAGCCTTCTGGGGGTGCTATGAGGTGATCCGTCCCCACACATGGG
ATGGGGGAGGCAGAGACTGGTCCAGAGCCCGCAAATGGACTCGGAGCCGAGGGCCTCCCAGCAGAGCTTGGGAAGGGCCATGGACCCAAC
TGGGCCCCAGAAGAGCCACAGGAACATCATTCCTCTCCCGCAACCACTCCCACCCCAGGGAGGCCCTGGCCTCCAGTGCCTTCCCCCGTG

>51206_51206_1_MAP2K4-CD79B_MAP2K4_chr17_11924318_ENST00000353533_CD79B_chr17_62008748_ENST00000006750_length(amino acids)=382AA_BP=0
MMFLWLFWGPVGSMALPKLCWEALGSESICGLWTSLCLPHPMCGDGSPHSTPRRLGPVHPQRTPSKLLPCCPSTPGPLARAGDQGLETNG
SSGGPASEASWGVQERGWAMSQAAPKQSLRPGSLHPGHGATWLSLLAWVLTYRPLHFPCPQRHYVLIGGCLVNVQALVGVIFLHASLAVI
LVQQQEDRHDDEEDDQQRLDHDDTILQRVPLLQLCQGAESHDSQLCAAALVDLRGVVALLLTEVDAIVLKPDALDGEGGERFVLGLFHAA
LFQLQLLGILVHLLLPEPAHIAGGAVHVAVHFHREAPFPGYETWALPDPRTSTTFGIPVPVLRSGCWYWLSLHAADGRVAWRRGPYGAGG

--------------------------------------------------------------
>51206_51206_2_MAP2K4-CD79B_MAP2K4_chr17_11924318_ENST00000353533_CD79B_chr17_62008748_ENST00000349817_length(transcript)=489nt_BP=178nt
GCGAGAGGCCGAGCTTGCTGCATTGCAGCCGCCGCGGCGCCGCTCGGCTCTTCACTCCCAACAATGGCGGCTCCGAGCCCGAGCGGCGGC
GGCGGCTCCGGGGGCGGCAGCGGCAGCGGCACCCCCGGCCCCGTAGGGTCCCCGGCGCCAGGCCACCCGGCCGTCAGCAGCATGCAGGCT
GAGCCAGTACCAGCAGCCAGATCGGAGGACCGGTACCGGAATCCCAAAGGATTCAGCACCTTGGCACAGCTGAAGCAGAGGAACACGCTG
AAGGATGGTATCATCATGATCCAGACGCTGCTGATCATCCTCTTCATCATCGTGCCTATCTTCCTGCTGCTGGACAAGGATGACAGCAAG
GCTGGCATGGAGGAAGATCACACCTACGAGGGCCTGGACATTGACCAGACAGCCACCTATGAGGACATAGTGACGCTGCGGACAGGGGAA

>51206_51206_2_MAP2K4-CD79B_MAP2K4_chr17_11924318_ENST00000353533_CD79B_chr17_62008748_ENST00000349817_length(amino acids)=143AA_BP=1
MAWVLTYRPLHFPCPQRHYVLIGGCLVNVQALVGVIFLHASLAVILVQQQEDRHDDEEDDQQRLDHDDTILQRVPLLQLCQGAESFGIPV

--------------------------------------------------------------
>51206_51206_3_MAP2K4-CD79B_MAP2K4_chr17_11924318_ENST00000353533_CD79B_chr17_62008748_ENST00000392795_length(transcript)=1290nt_BP=178nt
GCGAGAGGCCGAGCTTGCTGCATTGCAGCCGCCGCGGCGCCGCTCGGCTCTTCACTCCCAACAATGGCGGCTCCGAGCCCGAGCGGCGGC
GGCGGCTCCGGGGGCGGCAGCGGCAGCGGCACCCCCGGCCCCGTAGGGTCCCCGGCGCCAGGCCACCCGGCCGTCAGCAGCATGCAGGCA
GCTGAGCCAGTACCAGCAGCCAGATCGGAGGACCGGTACCGGAATCCCAAAGGTAGTGCTTGTTCGCGGATCTGGCAGAGCCCACGTTTC
ATAGCCAGGAAACGGGGCTTCACGGTGAAAATGCACTGCTACATGAACAGCGCCTCCGGCAATGTGAGCTGGCTCTGGAAGCAGGAGATG
GACGAGAATCCCCAGCAGCTGAAGCTGGAAAAGGGCCGCATGGAAGAGTCCCAGAACGAATCTCTCGCCACCCTCACCATCCAAGGCATC
CGGTTTGAGGACAATGGCATCTACTTCTGTCAGCAGAAGTGCAACAACACCTCGGAGGTCTACCAGGGCTGCGGCACAGAGCTGCGAGTC
ATGGGATTCAGCACCTTGGCACAGCTGAAGCAGAGGAACACGCTGAAGGATGGTATCATCATGATCCAGACGCTGCTGATCATCCTCTTC
ATCATCGTGCCTATCTTCCTGCTGCTGGACAAGGATGACAGCAAGGCTGGCATGGAGGAAGATCACACCTACGAGGGCCTGGACATTGAC
CAGACAGCCACCTATGAGGACATAGTGACGCTGCGGACAGGGGAAGTGAAGTGGTCTGTAGGTGAGCACCCAGGCCAGGAGTGAGAGCCA
GGTCGCCCCATGACCTGGGTGCAGGCTCCCTGGCCTCAGTGACTGCTTCGGAGCTGCCTGGCTCATGGCCCAACCCCTTTCCTGGACCCC
CCAGCTGGCCTCTGAAGCTGGCCCACCAGAGCTGCCATTTGTCTCCAGCCCCTGGTCCCCAGCTCTTGCCAAAGGGCCTGGAGTAGAAGG
ACAACAGGGCAGCAACTTGGAGGGAGTTCTCTGGGGATGGACGGGACCCAGCCTTCTGGGGGTGCTATGAGGTGATCCGTCCCCACACAT
GGGATGGGGGAGGCAGAGACTGGTCCAGAGCCCGCAAATGGACTCGGAGCCGAGGGCCTCCCAGCAGAGCTTGGGAAGGGCCATGGACCC
AACTGGGCCCCAGAAGAGCCACAGGAACATCATTCCTCTCCCGCAACCACTCCCACCCCAGGGAGGCCCTGGCCTCCAGTGCCTTCCCCC

>51206_51206_3_MAP2K4-CD79B_MAP2K4_chr17_11924318_ENST00000353533_CD79B_chr17_62008748_ENST00000392795_length(amino acids)=383AA_BP=0
MMFLWLFWGPVGSMALPKLCWEALGSESICGLWTSLCLPHPMCGDGSPHSTPRRLGPVHPQRTPSKLLPCCPSTPGPLARAGDQGLETNG
SSGGPASEASWGVQERGWAMSQAAPKQSLRPGSLHPGHGATWLSLLAWVLTYRPLHFPCPQRHYVLIGGCLVNVQALVGVIFLHASLAVI
LVQQQEDRHDDEEDDQQRLDHDDTILQRVPLLQLCQGAESHDSQLCAAALVDLRGVVALLLTEVDAIVLKPDALDGEGGERFVLGLFHAA
LFQLQLLGILVHLLLPEPAHIAGGAVHVAVHFHREAPFPGYETWALPDPRTSTTFGIPVPVLRSGCWYWLSCLHAADGRVAWRRGPYGAG

--------------------------------------------------------------
>51206_51206_4_MAP2K4-CD79B_MAP2K4_chr17_11924318_ENST00000415385_CD79B_chr17_62008748_ENST00000006750_length(transcript)=1277nt_BP=168nt
GAGCTTGCTGCATTGCAGCCGCCGCGGCGCCGCTCGGCTCTTCACTCCCAACAATGGCGGCTCCGAGCCCGAGCGGCGGCGGCGGCTCCG
GGGGCGGCAGCGGCAGCGGCACCCCCGGCCCCGTAGGGTCCCCGGCGCCAGGCCACCCGGCCGTCAGCAGCATGCAGGCTGAGCCAGTAC
CAGCAGCCAGATCGGAGGACCGGTACCGGAATCCCAAAGGTAGTGCTTGTTCGCGGATCTGGCAGAGCCCACGTTTCATAGCCAGGAAAC
GGGGCTTCACGGTGAAAATGCACTGCTACATGAACAGCGCCTCCGGCAATGTGAGCTGGCTCTGGAAGCAGGAGATGGACGAGAATCCCC
AGCAGCTGAAGCTGGAAAAGGGCCGCATGGAAGAGTCCCAGAACGAATCTCTCGCCACCCTCACCATCCAAGGCATCCGGTTTGAGGACA
ATGGCATCTACTTCTGTCAGCAGAAGTGCAACAACACCTCGGAGGTCTACCAGGGCTGCGGCACAGAGCTGCGAGTCATGGGATTCAGCA
CCTTGGCACAGCTGAAGCAGAGGAACACGCTGAAGGATGGTATCATCATGATCCAGACGCTGCTGATCATCCTCTTCATCATCGTGCCTA
TCTTCCTGCTGCTGGACAAGGATGACAGCAAGGCTGGCATGGAGGAAGATCACACCTACGAGGGCCTGGACATTGACCAGACAGCCACCT
ATGAGGACATAGTGACGCTGCGGACAGGGGAAGTGAAGTGGTCTGTAGGTGAGCACCCAGGCCAGGAGTGAGAGCCAGGTCGCCCCATGA
CCTGGGTGCAGGCTCCCTGGCCTCAGTGACTGCTTCGGAGCTGCCTGGCTCATGGCCCAACCCCTTTCCTGGACCCCCCAGCTGGCCTCT
GAAGCTGGCCCACCAGAGCTGCCATTTGTCTCCAGCCCCTGGTCCCCAGCTCTTGCCAAAGGGCCTGGAGTAGAAGGACAACAGGGCAGC
AACTTGGAGGGAGTTCTCTGGGGATGGACGGGACCCAGCCTTCTGGGGGTGCTATGAGGTGATCCGTCCCCACACATGGGATGGGGGAGG
CAGAGACTGGTCCAGAGCCCGCAAATGGACTCGGAGCCGAGGGCCTCCCAGCAGAGCTTGGGAAGGGCCATGGACCCAACTGGGCCCCAG
AAGAGCCACAGGAACATCATTCCTCTCCCGCAACCACTCCCACCCCAGGGAGGCCCTGGCCTCCAGTGCCTTCCCCCGTGGAATAAACGG

>51206_51206_4_MAP2K4-CD79B_MAP2K4_chr17_11924318_ENST00000415385_CD79B_chr17_62008748_ENST00000006750_length(amino acids)=382AA_BP=0
MMFLWLFWGPVGSMALPKLCWEALGSESICGLWTSLCLPHPMCGDGSPHSTPRRLGPVHPQRTPSKLLPCCPSTPGPLARAGDQGLETNG
SSGGPASEASWGVQERGWAMSQAAPKQSLRPGSLHPGHGATWLSLLAWVLTYRPLHFPCPQRHYVLIGGCLVNVQALVGVIFLHASLAVI
LVQQQEDRHDDEEDDQQRLDHDDTILQRVPLLQLCQGAESHDSQLCAAALVDLRGVVALLLTEVDAIVLKPDALDGEGGERFVLGLFHAA
LFQLQLLGILVHLLLPEPAHIAGGAVHVAVHFHREAPFPGYETWALPDPRTSTTFGIPVPVLRSGCWYWLSLHAADGRVAWRRGPYGAGG

--------------------------------------------------------------
>51206_51206_5_MAP2K4-CD79B_MAP2K4_chr17_11924318_ENST00000415385_CD79B_chr17_62008748_ENST00000349817_length(transcript)=479nt_BP=168nt
GAGCTTGCTGCATTGCAGCCGCCGCGGCGCCGCTCGGCTCTTCACTCCCAACAATGGCGGCTCCGAGCCCGAGCGGCGGCGGCGGCTCCG
GGGGCGGCAGCGGCAGCGGCACCCCCGGCCCCGTAGGGTCCCCGGCGCCAGGCCACCCGGCCGTCAGCAGCATGCAGGCTGAGCCAGTAC
CAGCAGCCAGATCGGAGGACCGGTACCGGAATCCCAAAGGATTCAGCACCTTGGCACAGCTGAAGCAGAGGAACACGCTGAAGGATGGTA
TCATCATGATCCAGACGCTGCTGATCATCCTCTTCATCATCGTGCCTATCTTCCTGCTGCTGGACAAGGATGACAGCAAGGCTGGCATGG
AGGAAGATCACACCTACGAGGGCCTGGACATTGACCAGACAGCCACCTATGAGGACATAGTGACGCTGCGGACAGGGGAAGTGAAGTGGT

>51206_51206_5_MAP2K4-CD79B_MAP2K4_chr17_11924318_ENST00000415385_CD79B_chr17_62008748_ENST00000349817_length(amino acids)=143AA_BP=1
MAWVLTYRPLHFPCPQRHYVLIGGCLVNVQALVGVIFLHASLAVILVQQQEDRHDDEEDDQQRLDHDDTILQRVPLLQLCQGAESFGIPV

--------------------------------------------------------------
>51206_51206_6_MAP2K4-CD79B_MAP2K4_chr17_11924318_ENST00000415385_CD79B_chr17_62008748_ENST00000392795_length(transcript)=1280nt_BP=168nt
GAGCTTGCTGCATTGCAGCCGCCGCGGCGCCGCTCGGCTCTTCACTCCCAACAATGGCGGCTCCGAGCCCGAGCGGCGGCGGCGGCTCCG
GGGGCGGCAGCGGCAGCGGCACCCCCGGCCCCGTAGGGTCCCCGGCGCCAGGCCACCCGGCCGTCAGCAGCATGCAGGCAGCTGAGCCAG
TACCAGCAGCCAGATCGGAGGACCGGTACCGGAATCCCAAAGGTAGTGCTTGTTCGCGGATCTGGCAGAGCCCACGTTTCATAGCCAGGA
AACGGGGCTTCACGGTGAAAATGCACTGCTACATGAACAGCGCCTCCGGCAATGTGAGCTGGCTCTGGAAGCAGGAGATGGACGAGAATC
CCCAGCAGCTGAAGCTGGAAAAGGGCCGCATGGAAGAGTCCCAGAACGAATCTCTCGCCACCCTCACCATCCAAGGCATCCGGTTTGAGG
ACAATGGCATCTACTTCTGTCAGCAGAAGTGCAACAACACCTCGGAGGTCTACCAGGGCTGCGGCACAGAGCTGCGAGTCATGGGATTCA
GCACCTTGGCACAGCTGAAGCAGAGGAACACGCTGAAGGATGGTATCATCATGATCCAGACGCTGCTGATCATCCTCTTCATCATCGTGC
CTATCTTCCTGCTGCTGGACAAGGATGACAGCAAGGCTGGCATGGAGGAAGATCACACCTACGAGGGCCTGGACATTGACCAGACAGCCA
CCTATGAGGACATAGTGACGCTGCGGACAGGGGAAGTGAAGTGGTCTGTAGGTGAGCACCCAGGCCAGGAGTGAGAGCCAGGTCGCCCCA
TGACCTGGGTGCAGGCTCCCTGGCCTCAGTGACTGCTTCGGAGCTGCCTGGCTCATGGCCCAACCCCTTTCCTGGACCCCCCAGCTGGCC
TCTGAAGCTGGCCCACCAGAGCTGCCATTTGTCTCCAGCCCCTGGTCCCCAGCTCTTGCCAAAGGGCCTGGAGTAGAAGGACAACAGGGC
AGCAACTTGGAGGGAGTTCTCTGGGGATGGACGGGACCCAGCCTTCTGGGGGTGCTATGAGGTGATCCGTCCCCACACATGGGATGGGGG
AGGCAGAGACTGGTCCAGAGCCCGCAAATGGACTCGGAGCCGAGGGCCTCCCAGCAGAGCTTGGGAAGGGCCATGGACCCAACTGGGCCC
CAGAAGAGCCACAGGAACATCATTCCTCTCCCGCAACCACTCCCACCCCAGGGAGGCCCTGGCCTCCAGTGCCTTCCCCCGTGGAATAAA

>51206_51206_6_MAP2K4-CD79B_MAP2K4_chr17_11924318_ENST00000415385_CD79B_chr17_62008748_ENST00000392795_length(amino acids)=383AA_BP=0
MMFLWLFWGPVGSMALPKLCWEALGSESICGLWTSLCLPHPMCGDGSPHSTPRRLGPVHPQRTPSKLLPCCPSTPGPLARAGDQGLETNG
SSGGPASEASWGVQERGWAMSQAAPKQSLRPGSLHPGHGATWLSLLAWVLTYRPLHFPCPQRHYVLIGGCLVNVQALVGVIFLHASLAVI
LVQQQEDRHDDEEDDQQRLDHDDTILQRVPLLQLCQGAESHDSQLCAAALVDLRGVVALLLTEVDAIVLKPDALDGEGGERFVLGLFHAA
LFQLQLLGILVHLLLPEPAHIAGGAVHVAVHFHREAPFPGYETWALPDPRTSTTFGIPVPVLRSGCWYWLSCLHAADGRVAWRRGPYGAG

--------------------------------------------------------------

Top

Fusion Gene PPI Analysis for MAP2K4-CD79B

Go to ChiPPI (Chimeric Protein-Protein interactions) to see the chimeric PPI interaction in
ChiPPI page.

Protein-protein interactors with each fusion partner protein in wild-type (BIOGRID-3.4.160)

Hgene

Hgene's interactors

Tgene

Tgene's interactors

- Retained PPIs in in-frame fusion.

Partner

Gene

Hbp

Tbp

ENST

Strand

BPexon

TotalExon

Protein feature loci

*BPloci

TotalLen

Still interaction with

- Lost PPIs in in-frame fusion.

Partner

Gene

Hbp

Tbp

ENST

Strand

BPexon

TotalExon

Protein feature loci

*BPloci

TotalLen

Interaction lost with

- Retained PPIs, but lost function due to frame-shift fusion.

Partner

Gene

Hbp

Tbp

ENST

Strand

BPexon

TotalExon

Protein feature loci

*BPloci

TotalLen

Interaction lost with

Top

Related Drugs for MAP2K4-CD79B

Drugs targeting genes involved in this fusion gene.
(DrugBank Version 5.1.8 2021-05-08)

Partner

Gene

UniProtAcc

DrugBank ID

Drug name

Drug activity

Drug type

Drug status

Top

Related Diseases for MAP2K4-CD79B

Diseases associated with fusion partners.
(DisGeNet 4.0)

Partner

Gene

Disease ID

Disease name

# pubmeds

Source